Startup profile for TestDynamics: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

TestDynamics funding, valuation and investors

Vendor-neutral imaging-AI evaluation, integration and governance for hospitals and radiology groups.

Verified company research · funding, investors and latest developments

Keep track of TestDynamics

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A announced; amount represents issuer's $9M funding disclosure, Series A tranche not separately specified

$9M disclosed funding (tranche split undisclosed) · November 16, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$9M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · Austin, Texas, United States

Investors in latest funding

Lead: Healthier Capital

Other: Cedars-Sinai Technology Ventures

Sources: latest funding · businesswire.com Last verified: 2026-11-18

Overview

Austin, Texas-based TestDynamics announced on 16 November 2026 that it secured $9M in funding, with its Series A led by Healthier Capital and Cedars-Sinai Technology Ventures participating. The original release does not expressly split an individual Series A tranche from other funding.

Its Satori platform helps hospitals independently evaluate third-party imaging algorithms on de-identified local studies, integrate selected tools with radiology systems and monitor results after rollout. TestDynamics reports clinical use at several large US medical centers, but names, clinical outcomes, revenue and pricing are not independently confirmed.

Why TestDynamics is interesting

Hospitals need to test, buy, monitor and replace competing FDA-cleared imaging algorithms; Satori offers one clinical contract and connector rather than one procurement/integration per algorithm. The disclosed $9M covers a financing announcement involving a Series A, not necessarily a fully specified $9M Series A tranche.

Product & use cases

Illustrative hospital workflow from TestDynamics's published Satori implementation stages (not a hands-on test): (1) clinical AI committee sets imaging use cases and measurable goals; (2) sign one contract and BAA, deploy Satori Edge connected to PACS, worklists and reporting systems; (3) test candidate FDA-cleared algorithms side-by-side on the hospital's de-identified studies, with clinician review; (4) integrate selected results in Satori View while radiologists approve findings before reporting; (5) monitor drift, clinician overrides, usage and performance after launch, retaining ability to swap poorly performing vendors. Vendor publishes staged 2–6 week connections, up-to-30-day algorithm trials and 90-day value review as typical process, not proven SLA. Enterprise price is quote-based/undisclosed.

  • Hospital comparison and local validation of competing medical imaging algorithms
  • Single-contract radiology AI procurement and clinical system integration
  • Postdeployment drift monitoring, clinician overrides and reporting

Key facts

  • Issuer Business Wire release 2026-11-16: $9M funding announced, Series A led by Healthier Capital; Cedars-Sinai Technology Ventures participated. https://www.businesswire.com/news/home/20261116497451/en/
  • The original release does not state the new Series A tranche size separately, so $9M is recorded as total announced funding, not a mathematically proven single-round amount.
  • Vendor Satori implementation stages and single BAA/PACS workflow: https://testdynamics.net/platform/
  • Vendor-selected clinical-use claims must not be interpreted as clinical outcome evidence or FDA clearance for the Satori platform.

Funding history (newest first)

Series A announced; amount represents issuer's $9M funding disclosure, Series A tranche not separately specified

2026-11-16 $9M disclosed funding (tranche split undisclosed)
  • Healthier Capital (lead)
  • Cedars-Sinai Technology Ventures (participant)

Source: Read source · businesswire.com

Competitive landscape

Edge: Satori combines vendor-neutral evaluation and ongoing monitoring with procurement and integrations; vendor independence, local-data generalizability and outcome improvements require external validation.

One contract does not prove cheaper net total costs; algorithm/vendor fees, deployment, oversight, BAA and governance require review. No published price or independent comparative sensitivity/specificity. Vendor says Satori uses cleared algorithms but does not itself analyze images or claim its own FDA clearance. The 2026-11-16 issuer wording 'secured $9M in funding, with its Series A...' leaves tranche versus cumulative distinction unresolved.

  • Direct imaging AI vendor purchases incumbent

    Each vendor's own contract/integration/benchmarks; Satori offers cross-vendor program management.

  • Hospital-built algorithm evaluation program alternative

    Clinical team can run independent studies with local PACS and analytics, but incurs staff/integration costs.

  • Blackford Analysis direct

    Medical imaging AI platform/marketplace; compare vendor neutrality, workflow and evaluation methods.

  • Nuance Precision Imaging Network adjacent

    Enterprise imaging AI distribution/integration ecosystem; commercial and validation models differ.

Market / IPO context

Editorial / static context — not a live quote.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.